JP2015078201A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015078201A5 JP2015078201A5 JP2014233012A JP2014233012A JP2015078201A5 JP 2015078201 A5 JP2015078201 A5 JP 2015078201A5 JP 2014233012 A JP2014233012 A JP 2014233012A JP 2014233012 A JP2014233012 A JP 2014233012A JP 2015078201 A5 JP2015078201 A5 JP 2015078201A5
- Authority
- JP
- Japan
- Prior art keywords
- solid pharmaceutical
- group
- acid
- pharmaceutical composition
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000005843 halogen group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000007787 solid Substances 0.000 claims 8
- 230000002378 acidificating effect Effects 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000003796 beauty Effects 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 235000010443 alginic acid Nutrition 0.000 claims 2
- 239000000783 alginic acid Substances 0.000 claims 2
- 229960001126 alginic acid Drugs 0.000 claims 2
- 229920000615 alginic acid Polymers 0.000 claims 2
- 150000004781 alginic acids Chemical class 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 238000007908 dry granulation Methods 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 239000001530 fumaric acid Substances 0.000 claims 2
- 235000011087 fumaric acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 claims 2
- 235000018342 monosodium citrate Nutrition 0.000 claims 2
- 239000002524 monosodium citrate Substances 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 229960003707 glutamic acid hydrochloride Drugs 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014233012A JP6391436B2 (ja) | 2013-04-25 | 2014-11-17 | 固形医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013092171 | 2013-04-25 | ||
| JP2013092171 | 2013-04-25 | ||
| JP2014233012A JP6391436B2 (ja) | 2013-04-25 | 2014-11-17 | 固形医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541237A Division JP5651812B1 (ja) | 2013-04-25 | 2014-04-24 | 固形医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015078201A JP2015078201A (ja) | 2015-04-23 |
| JP2015078201A5 true JP2015078201A5 (enExample) | 2017-06-15 |
| JP6391436B2 JP6391436B2 (ja) | 2018-09-19 |
Family
ID=51791434
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541237A Active JP5651812B1 (ja) | 2013-04-25 | 2014-04-24 | 固形医薬組成物 |
| JP2014233012A Active JP6391436B2 (ja) | 2013-04-25 | 2014-11-17 | 固形医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541237A Active JP5651812B1 (ja) | 2013-04-25 | 2014-04-24 | 固形医薬組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9603804B2 (enExample) |
| EP (1) | EP2990038B1 (enExample) |
| JP (2) | JP5651812B1 (enExample) |
| CN (1) | CN105338982B (enExample) |
| CA (1) | CA2910112C (enExample) |
| ES (1) | ES2768651T3 (enExample) |
| WO (1) | WO2014174846A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9687453B2 (en) | 2013-04-25 | 2017-06-27 | Kyorin Pharmaceutical Co., Ltd. | Solid pharmaceutical composition |
| US10154993B2 (en) * | 2014-10-23 | 2018-12-18 | Kyorin Pharmaceutical Co., Ltd. | Solid pharmaceutical composition |
| EP3210608A4 (en) * | 2014-10-23 | 2018-06-20 | Kyorin Pharmaceutical Co., Ltd. | Solid pharmaceutical composition |
| JP6031217B1 (ja) * | 2015-06-02 | 2016-11-24 | 杏林製薬株式会社 | 水性液剤 |
| WO2016195020A1 (ja) * | 2015-06-02 | 2016-12-08 | 杏林製薬株式会社 | 水性液剤 |
| JP6031216B1 (ja) * | 2015-06-02 | 2016-11-24 | 杏林製薬株式会社 | 水性液剤 |
| EP3773579A4 (en) | 2018-03-26 | 2022-03-09 | Clear Creek Bio, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE |
| AU2021236757A1 (en) * | 2020-03-20 | 2022-10-13 | Clear Creek Bio, Inc. | Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof |
| WO2021189018A1 (en) | 2020-03-20 | 2021-09-23 | Clear Creek Bio, Inc. | Methods of treating viral infections using inhibitors of nucleotide synthesis pathways |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8524001D0 (en) | 1985-09-30 | 1985-11-06 | Glaxo Group Ltd | Pharmaceutical composition |
| ZA87279B (en) | 1986-01-17 | 1987-09-30 | Chugai Pharmaceutical Co Ltd | Method for production of stable nicorandil preparation |
| KR940000232B1 (ko) | 1986-01-17 | 1994-01-12 | 쥬우가이세이야꾸 가부시끼가이샤 | 니코란딜 제제의 안정화 방법 |
| JP2512302B2 (ja) | 1986-03-19 | 1996-07-03 | 中外製薬株式会社 | ニコランジル安定化製剤の製造方法 |
| WO1990007327A1 (fr) | 1988-12-28 | 1990-07-12 | Taisho Pharmaceutical Co., Ltd. | Procede de dispersion des contraintes lors d'une operation de mise en tablettes |
| TW284688B (enExample) | 1991-11-20 | 1996-09-01 | Takeda Pharm Industry Co Ltd | |
| JP2682353B2 (ja) | 1991-11-20 | 1997-11-26 | 武田薬品工業株式会社 | 経口用医薬組成物およびその製造法 |
| JP2006111639A (ja) | 1993-10-21 | 2006-04-27 | Takeda Chem Ind Ltd | 医薬用錠剤 |
| JPH08175996A (ja) | 1994-12-22 | 1996-07-09 | Taiyo Yakuhin Kogyo Kk | ニコランジル安定化固形製剤の製法 |
| JP3119801B2 (ja) | 1995-09-28 | 2000-12-25 | 武田薬品工業株式会社 | ビタミン含有組成物の安定化方法 |
| JPH10245335A (ja) | 1997-02-28 | 1998-09-14 | Dainippon Pharmaceut Co Ltd | 圧力に不安定な薬物の打錠方法及びそれに用いられる湿潤顆粒 |
| CA2322432C (en) | 1998-03-03 | 2005-12-20 | Daewoong Pharmaceutical Co., Ltd. | Pharmaceutical composition containing cefuroxime axetil stable for moisture absorption |
| AT413647B (de) | 1998-11-26 | 2006-04-15 | Sandoz Ag | Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten |
| DE10048510A1 (de) | 2000-09-29 | 2002-05-16 | Fresenius Kabi De Gmbh | Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt |
| ATE303149T1 (de) | 2001-02-27 | 2005-09-15 | Ranbaxy Lab Ltd | Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil |
| US7219132B2 (en) | 2001-03-30 | 2007-05-15 | Space Systems/Loral | Dynamic resource allocation architecture for differentiated services over broadband communication networks |
| KR20040094806A (ko) * | 2002-03-18 | 2004-11-10 | 교린 세이야꾸 가부시키 가이샤 | 내성균에 유효한10-(3-시클로프로필아미노메틸-1-피로리디닐)피리도벤즈옥사진 카르본산 유도체 |
| EP1459739B1 (en) | 2003-03-19 | 2008-01-02 | The Jordanian Pharmaceutical Manufacturing Co. Ltd. | Non-hygroscopic pharmaceutical compositions containing non-hydrated quinoline carboxylic acids |
| WO2005026147A1 (ja) * | 2003-09-10 | 2005-03-24 | Kyorin Pharmaceutical Co., Ltd. | ７−（４−置換−３−シクロプロピルアミノメチル−１−ピロリジニル）キノロンカルボン酸誘導体 |
| AU2005258398A1 (en) | 2004-07-02 | 2006-01-12 | Daiichi Pharmaceutical Co., Ltd. | Quinolone-containing medicinal composition |
| ATE428421T1 (de) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| JPWO2006059716A1 (ja) | 2004-12-03 | 2008-06-05 | 武田薬品工業株式会社 | 固形製剤 |
| AR053662A1 (es) | 2005-01-21 | 2007-05-16 | Astex Therapeutics Ltd | Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk |
| WO2006079496A1 (en) | 2005-01-26 | 2006-08-03 | Lek Pharmaceuticals D.D. | New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance |
| JP2006298811A (ja) | 2005-04-20 | 2006-11-02 | Taiyo Yakuhin Kogyo Kk | ゲル化抑制製剤の設計 |
| SA112330992B1 (ar) | 2011-11-10 | 2015-09-13 | كيورين فارماسوتيكال كو.، ليمتد | صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي |
| JP6050322B2 (ja) | 2012-03-29 | 2016-12-21 | 杏林製薬株式会社 | カプセル製剤 |
| JP6062422B2 (ja) | 2012-03-29 | 2017-01-18 | 杏林製薬株式会社 | カプセル製剤 |
| US9687453B2 (en) * | 2013-04-25 | 2017-06-27 | Kyorin Pharmaceutical Co., Ltd. | Solid pharmaceutical composition |
-
2014
- 2014-04-24 CA CA2910112A patent/CA2910112C/en not_active Expired - Fee Related
- 2014-04-24 US US14/786,394 patent/US9603804B2/en not_active Expired - Fee Related
- 2014-04-24 CN CN201480036231.6A patent/CN105338982B/zh active Active
- 2014-04-24 JP JP2014541237A patent/JP5651812B1/ja active Active
- 2014-04-24 ES ES14787908T patent/ES2768651T3/es active Active
- 2014-04-24 EP EP14787908.4A patent/EP2990038B1/en active Active
- 2014-04-24 WO PCT/JP2014/002308 patent/WO2014174846A1/ja not_active Ceased
- 2014-11-17 JP JP2014233012A patent/JP6391436B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015078201A5 (enExample) | ||
| SA517390583B1 (ar) | مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| ZA201507958B (en) | New somatostatin receptor subtype 4 (sstr4)agonists | |
| JP2018531941A5 (enExample) | ||
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| TN2016000581A1 (en) | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | |
| CN108026053A8 (zh) | 作为mIDH1抑制剂的稠合的咪唑类化合物 | |
| CY1113676T1 (el) | Υποκατεστημενο βητα-φαινυλο-αλφα-υδροξυ προπιονικο οξυ, μεθοδος συνθεσης και χρηση του | |
| JP2015110646A5 (enExample) | ||
| MY160785A (en) | Manufacturing process for pyrimidine derivatives | |
| HRP20241103T1 (hr) | 2,4-di-(skupina koja sadrži dušik)-supstituirani pirimidinski spoj i postupak pripreme i njegova upotreba | |
| ZA201805185B (en) | Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms | |
| MX2021006790A (es) | Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina. | |
| EA201691136A1 (ru) | Производное на основе 1,2-нафтохинона и способ его получения | |
| JP2016531126A5 (enExample) | ||
| MX2016001096A (es) | Sales de dasatinib en forma amorfa. | |
| EA201691538A1 (ru) | Способ получения солей вортиоксетина | |
| CN110891950A (zh) | 一种三嗪化合物及其药学上可接受的盐 | |
| MX379859B (es) | Compuestos de indolinona y su uso en el tratamiento de enfermedades fibróticas. | |
| MX2016001095A (es) | Sales de dasatinib en forma cristalina. | |
| PH12019500822B1 (en) | Crystalline forms of eravacycline | |
| MA39715A (fr) | Formes polymorphes de l'acide 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylique et de son sel de disodium, procédé de préparation desdites formes polymorphes et leur utilisation | |
| EA201892020A1 (ru) | Индольные производные и их применение в качестве ингибиторов протеинкиназы | |
| EA201591704A1 (ru) | Новые устойчивые соли пентадекапептида, способ их получения, их применение в производстве фармацевтических составов и их применение в терапии |